Lapides Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Lapides Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-21,000	Closed	-$300K	–	91
2017 Q3	$300K	Hold	21,000	–	–	0.06%	85
2017 Q2	$331K	Sell	21,000 -7,300	-26%	-$105K	0.06%	80
2017 Q1	$391K	Buy	+28,300	New	+$396K	0.07%	77

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Lapides Asset Management's VIVO Position: Q4 2017 in Review

Lapides Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2017, closing a stake of 21,000 shares — an estimated $300K sold.

Lapides Asset Management first reported a position in VIVO in Q1 2017 and held it in 3 quarters. The position peaked at $391K in Q1 2017. 178 funds tracked by Wall St. Rank hold VIVO as of Q4 2017.

Lapides Asset Management reported no remaining Meridian Bioscience Inc position as of Q4 2017 after selling out during the quarter.
Lapides Asset Management sold 21,000 Meridian Bioscience Inc shares in Q4 2017, an estimated $300K.
Lapides Asset Management first reported a position in Meridian Bioscience Inc in Q1 2017 and held it in 3 quarters.
Lapides Asset Management's Meridian Bioscience Inc position peaked at $391K in Q1 2017.
178 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2017.

Based on Lapides Asset Management's 13F filing for Q4 2017, filed 8 Feb 2018.